Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Moderna (MRNA) Shares Rally After Topping Q2 Estimates
August 3, 2022 9:58 AM EDTModerna (NASDAQ: MRNA) shares jumped more than 13% in early Wednesday trading after it posted earnings before the open Wednesday, topping analyst earnings and revenue consensus estimates.
The pharmaceutical company revealed second-quarter earnings of $5.24 per share, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.
Moderna's said... More
Moderna (MRNA) announces new $3 billion share repurchase plan
August 3, 2022 7:11 AM EDTWith earnings, Moderna (NASDAQ: MRNA) announces a new $3 billion share repurchase plan.
Moderna (MRNA) Tops Q2 EPS by 70c, Beats on Revenue
August 3, 2022 7:02 AM EDTModerna (NASDAQ: MRNA) reported Q2 EPS of $5.24, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... More